 | |
| Author | Ben Goldacre |
|---|---|
| Subject | Pharmaceutical industry |
| Publisher | Fourth Estate (UK), Faber & Faber (US), Signal (Canada) |
Publication date | 25 September 2012 |
| Media type | Print (Hardcover and Paperback) |
| Pages | 430 (first edition) |
| ISBN | 978-0-00-735074-2 |
| Preceded by | Bad Science |
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by the British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products.[1] It was published in the UK in September 2012 by the Fourth Estate imprint of HarperCollins, and in the United States in February 2013 by Faber and Faber.
Goldacre argues in the book that "the whole edifice of medicine is broken", because the evidence on which it is based is systematically distorted by the pharmaceutical industry.[n 1] He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure.[3] Describing the situation as a "murderous disaster", he makes suggestions for action by patients' groups, physicians, academics and the industry itself.[4]
Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement in 2012 arguing that the examples the book offers were historical, that the concerns had been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.[5]
In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported.[6] The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.[7]
- ^ Luisa Dillner, "Bad Pharma by Ben Goldacre – review", The Guardian, 17 October 2012.
- ^ Ben Goldacre, Bad Pharma, Fourth Estate, 2012, ix.
- ^ Bad Pharma, x–xi, 287ff; "Pick your pill out of a hat", The Economist, 29 September 2012.
- ^ Bad Pharma, xii, 357ff.
- ^ "ABPI statement on Ben Goldacre's book 'Bad Pharma'" Archived 9 October 2012 at the Wayback Machine, Association of the British Pharmaceutical Industry, 5 October 2012.
Ben Adams, "Goldacre takes ABPI to task over book snub" Archived 7 January 2014 at the Wayback Machine, Pharma Times, 12 October 2012.
- ^ "About", alltrials.net; Tracey Brown, "It's time for AllTrials registered and reported" Archived 29 October 2013 at the Wayback Machine, The Cochrane Library, 30 April 2013.
- ^ David Tovey, "Why the Public Accounts Committee Report on Tamiflu Is Important for Us All", HuffPost, 3 January 2014.
Rajeev Syal, "Drug companies accused of holding back complete information on clinical trials", The Guardian, 3 January 2014.
Cite error: There are <ref group=n> tags on this page, but the references will not show without a {{reflist|group=n}} template (see the help page).